Intracellular delivery of major histocompatibility complex class I-binding epitopes: Dendritic cells loaded and matured with cationic peptide/poly(I:C) complexes efficiently activate T cells

Experimental Dermatology

Volumn 19, Issue 1, 2010, Pages 19-28

  Haenssle, Holger A ^a   Riedl, Petra ^b   Buhl, Timo ^a   Schardt, Anke ^c   Rosenberger, Albert ^a   Schön, Michael P ^a   Schirmbeck, Reinhold ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Cell penetrating peptide; Dendritic cells; Immunotherapy; Melanoma; Toll like receptor

Indexed keywords

ARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMYLARGINYLARGININE; CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CELL PENETRATING PEPTIDE; DOUBLE STRANDED RNA; EPITOPE; GLUTAMINYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; GLUTAMINYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMYLARGINYLARGININE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ARTICLE; CELL MATURATION; CELL VIABILITY; COMPLEX FORMATION; CONFOCAL LASER MICROSCOPY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INTERNALIZATION; LEUKAPHERESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CELL SURVIVAL; DENDRITIC CELLS; EPITOPES; GENES, MHC CLASS I; HUMANS; INTERFERON INDUCERS; INTERLEUKIN-12; MELANOMA; NEOPLASM PROTEINS; POLY I-C; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TOLL-LIKE RECEPTOR 3;

EID: 72549093499     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00954.x     Document Type: Article

References (47)

1. Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Moser M, Murphy K M. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000, 1:199-205.
3. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003, 21:873-886.
4. Schadendorf D, Ugurel S, Schuler-Thurner B. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006, 17:563-570.
5. Balkow S, Loser K, Krummen M. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol 2009, 18:78-87.
6. Fujisawa Y, Nabekura T, Nakao T. The induction of tumor-specific CD4 + T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Exp Dermatol 2009, 18:396-403.
7. Jonuleit H, Kuhn U, Muller G. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
8. Rouas R, Lewalle P, El Ouriaghli F, Nowak B, Duvillier H, Martiat P. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol 2004, 16:767-773.
9. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999, 189:821-829.
10. Verdijk R M, Mutis T, Esendam B. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 1999, 163:57-61.
11. Muzio M, Bosisio D, Polentarutti N. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000, 164:5998-6004.
12. Matsumoto M, Funami K, Tanabe M. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003, 171:3154-3162.
13. Lehner M, Morhart P, Stilper A. Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother 2007, 30:312-322.
14. Schulz O, Diebold S S, Chen M. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433:887-892.
15. Robinson R A, DeVita V T, Levy H B, Baron S, Hubbard S P, Levine A S. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976, 57:599-602.
16. Salazar A M, Levy H B, Ondra S. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996, 38:1096-1103.
17. Strayer D R, Carter W A, Brodsky I. A controlled clinical trial with a specifically configured RNA drug, poly(I)·poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994, 18(Suppl. 1):S88-S95.
18. Carter W A, Strayer D R, Brodsky I. Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1987, 1:1286-1292.
19. Gillespie D, Hubbell H R, Carter W A. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. In Vivo 1994, 8:375-381.
20. Banchereau J, Palucka A K, Dhodapkar M. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61:6451-6458.
21. Brossart P, Wirths S, Stuhler G, Reichardt V L, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102-3108.
22. Chromik J, Schnurer E, Georg M R. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. J Immunol Methods 2006, 308:77-89.
23. Ludewig B, McCoy K, Pericin M. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001, 166:3678-3687.
24. Dieckmann D, Schultz E S, Ring B. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int Immunol 2005, 17:621-635.
25. Green M, Loewenstein P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988, 55:1179-1188.
26. Frankel A D, Pabo C O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
27. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8:848-866.
28. Schirmbeck R, Riedl P, Zurbriggen R, Akira S, Reimann J. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4 + T cell help-independent, priming of CD8 + T cells. J Immunol 2003, 171:5198-5207.
29. Haenssle H, Buhl T, Knudsen S. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol 2008, 17:177-187.
30. Valmori D, Fonteneau J F, Lizana C M. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998, 160:1750-1758.
31. Pittet M J, Valmori D, Dunbar P R. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999, 190:705-715.
32. Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 2000, 23:289-295.
33. Jonuleit H, Giesecke-Tuettenberg A, Tuting T. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001, 93:243-251.
34. Schuler-Thurner B, Schultz E S, Berger T G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279-1288.
35. Riedl P, Reimann J, Schirmbeck R. Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8(+) T-cell-stimulating immunogens. Methods Mol Med 2006, 127:159-169.
36. Riedl P, Reimann J, Schirmbeck R. Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med 2004, 82:144-152.
37. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A, Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004, 16:1143-1154.
38. de Bouteiller O, Merck E, Hasan U A. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005, 280:38133-38145.
39. El Andaloussi S, Jarver P, Johansson H J, Langel U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 2007, 407:285-292.
40. Saar K, Lindgren M, Hansen M. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem 2005, 345:55-65.
41. Jones S W, Christison R, Bundell K. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 2005, 145:1093-1102.
42. Green I, Christison R, Voyce C J, Bundell K R, Lindsay M A. Protein transduction domains: are they delivering? Trends Pharmacol Sci 2003, 24:213-215.
43. Richard J P, Melikov K, Vives E. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003, 278:585-590.
44. Wang H Y, Fu T, Wang G. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002, 109:1463-1470.
45. Moller I, Michel K, Frech N. Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J Immunother 2008, 31:506-519.
46. Boullart A C, Aarntzen E H, Verdijk P. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008, 57:1589-1597.
47. Yoneyama M, Kikuchi M, Natsukawa T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.